BCRX:NSD-BioCryst Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 14.92

Change

-0.45 (-2.93)%

Market Cap

USD 2.75B

Volume

2.12M

Avg Analyst Target

USD 21.17 (+41.87%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina.

Company Website : http://www.biocryst.com

Address : 4505 Emperor Boulevard, Durham, NC, United States, 27703

Employees : 246

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.58

52 Week High : 18.48

Short Ratio : 5.93

52 Week Low : 3.36

Shorted Shares : 19,285,753

200 Day Moving Average : 14.34

Shorted Shares Previous Month : 20,538,133

50 Day Moving Average : 15.48

Shares Held By Insiders : 0.90%

Short Percentage : 11.00%

Shares Held by Institutions : 59.88%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-24.46 (-5.38%)

 USD183.50B 53.71 41.56
BNTX BioNTech SE

-19.51 (-5.53%)

 USD82.28B 18.73 15.10
REGN Regeneron Pharmaceuticals Inc

-7.61 (-1.18%)

 USD69.15B 11.67 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.48 (-0.80%)

 USD48.02B 24.40 16.63
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-5.90 (-1.53%)

 USD37.14B N/A N/A
SGEN Seagen Inc

-4.88 (-2.94%)

 USD30.24B 51.86 39.11
GMAB Genmab A/S

-1.45 (-3.23%)

 USD28.89B 73.39 8.17
RPRX Royalty Pharma plc

-0.03 (-0.08%)

 USD22.54B 30.06 12.50
ALNY Alnylam Pharmaceuticals Inc

+0.45 (+0.24%)

 USD22.22B N/A N/A

ETFs Containing BCRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 100.27% 92% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 100.27% 92% A- 94% A
Trailing 12 Months  
Capital Gain 309.89% 95% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 309.89% 95% A 96% A
Trailing 5 Years  
Capital Gain 216.77% 81% B- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 216.77% 81% B- 83% B
Average Annual (5 Year Horizon)  
Capital Gain 53.45% 76% C 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.45% 76% C 86% B
Risk Return Profile  
Volatility (Standard Deviation) 121.73% 22% F 13% F
Risk Adjusted Return 43.90% 71% C- 61% D-
Market Capitalization 2.75B 87% B+ 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 56.59 2% F 2% F
Price / Cash Flow Ratio -20.02 77% C+ 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -1,925.37% 2% F 9% F
Return on Invested Capital -140.60% 10% F 5% F
Return on Assets -46.05% 14% F 5% F
Debt to Equity Ratio -621.61% 99% A+ 98% A+
Technical Ratios  
Short Ratio 5.93 40% F 27% F
Short Percent 11.72% 17% F 13% F
Beta 2.58 5% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector